Either the market (discount future revenue) decide
Post# of 30027
Lympro deals may be structured with a hybrid of partnership(s) and full regional or application rights buyout(s), e.g.
US: partnership with a pharma, or full rights buyout for CTE+TBI
Europe: full rights buyout by same or different pharma, e.g. $800m (which likely levels AMBS market cap up by additional $800m)
China: full rights buyout, e.g. $600m (additional $600m market cap)
The confidence of Gerald in stating possibility of no RS on several occasions may stem from possible financial engineering approach to deals.